M&A Deal Summary |
|
|---|---|
| Date | 2023-03-07 |
| Target | Sesen Bio |
| Sector | Life Science |
| Buyer(s) | Carisma Therapeutics |
| Deal Type | Merger |
| Advisor(s) | Leerink Partners (Financial) Hogan Lovells (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2016 |
| Sector | Life Science |
| Employees | 46 |
| Revenue | 20M USD (2024) |
Carisma Therapeutics is a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidate includes CT-2401, which is in preclinical trail for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. Carisma Therapeutics was founded in 2016 and is based in Philadelphia, Pennsylvania.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Merger M&A Deals | 1 of 1 |
| State: Massachusetts M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2023 M&A | 1 of 1 |
